LONDON, Sept 6 A shareholder in Bayer said on Tuesday that the German chemical and crop pesticide firm's potential takeover of rival Monsanto represented significant risks for shareholders.
Late Monday, Bayer said it had sweetened its offer for Monsanto from $125 a share to $127.50 a share, to take the deal value to more than $65 billion.
Greg Herbert, co-manager of the Jupiter Global Equity Income Fund, said he had expected Bayer to come back with a revised offer, and the new deal terms were "probably getting closer to succeeding".
However, Herbert said the revised terms did not change his view that the deal presents significant risks.
"The company will be left with a highly geared balance sheet and the management effort to integrate the two businesses could easily lead to the larger pharmaceutical business being neglected," he wrote in emailed comments.
Jupiter Fund Management, a leading UK asset manager, is currently the 31st biggest shareholder in Bayer, given its holdings across several funds, out of a total of nearly 1,000 investors. (Reporting by Simon Jessop; Editing by Rachel Armstrong)
UPDATE 1-Milan court orders trial over Monte dei Paschi trades -legal sources
MILAN, Oct 1 A Milan court has ordered Banca Monte dei Paschi di Siena, Nomura and Deutsche Bank to stand trial for a string of alleged financial crimes, legal sources said on Saturday.
Texas businessman Wyly strikes $198 million deal with SEC
NEW YORK, Oct 1 Texas businessman Sam Wyly has agreed to pay $198.1 million to resolve claims by U.S. securities regulators that he engaged in a long-running securities fraud to hide trades in companies he controlled using offshore trusts, according to a court filing.